Literature DB >> 1569181

Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

A M Aly1, L W Hoyer.   

Abstract

Factor VIII East Hartford (FVIII-EH) procoagulant activity is reduced because the substitution of cysteine for arginine 1689 abolishes an essential Factor VIII light chain thrombin cleavage site. Incubation of FVIII-EH plasma with penicillamine or DTT causes a five- to sixfold increase in FVIII-EH VIII:C, at 80 and 1 mM, respectively. While there is no FVIII-EH light chain cleavage when thrombin is added in the presence of penicillamine or DTT, these reducing agents disrupt the FVIII-vWf complex. For example, the addition of 5 mM DTT to normal or FVIII-EH plasma causes a 50% reduction in Factor VIII binding to vWf. These observations suggested that DTT increases FVIII-EH VIII:C by partial dissociation of FVIII-EH from vWf. This was verified by showing that vWf-free FVIII-EH had VIII:C activity of 21 U/dl, while the starting plasma level was 2.5 U/dl. Removal of other FVIII-EH plasma proteins by agarose gel filtration had no effect on VIII:C activity. The demonstration that this mutant Factor VIII has cofactor function when separated from vWf indicates that the dissociation of Factor VIII from vWf is an essential effect of Factor VIII light chain cleavage at arginine-1689.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569181      PMCID: PMC443006          DOI: 10.1172/JCI115726

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.

Authors:  H A Cooper; F F Reisner; M Hall; R H Wagner
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

2.  Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for anthemophilic factor.

Authors:  R T BRECKENRIDGE; C D RATNOFF
Journal:  Blood       Date:  1962-08       Impact factor: 22.113

3.  Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.

Authors:  M Arai; M Higuchi; S E Antonarakis; H H Kazazian; J A Phillips; R L Janco; L W Hoyer
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

Review 4.  Structure-function relationships of factor VIII elucidated through recombinant DNA technology.

Authors:  D D Pittman; R J Kaufman
Journal:  Thromb Haemost       Date:  1989-04-25       Impact factor: 5.249

5.  Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.

Authors:  R B Counts; S L Paskell; S K Elgee
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

6.  Activation of factor X by factors IXa and VIII; a specific assay for factor IXa in the presence of thrombin-activated factor VIII.

Authors:  M B Hultin; Y Nemerson
Journal:  Blood       Date:  1978-11       Impact factor: 22.113

7.  Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies.

Authors:  F Rotblat; D P O'Brien; F J O'Brien; A H Goodall; E G Tuddenham
Journal:  Biochemistry       Date:  1985-07-30       Impact factor: 3.162

8.  Immunoradiometric measurement of the factor VIII procoagulant antigen.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

9.  Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine).

Authors:  M Arai; H Inaba; M Higuchi; S E Antonarakis; H H Kazazian; M Fujimaki; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

10.  Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.

Authors:  C A Fulcher; J R Roberts; L Z Holland; T S Zimmerman
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

View more
  2 in total

1.  Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).

Authors:  A M Aly; M Arai; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

2.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.